337 related articles for article (PubMed ID: 22367770)
1. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing global antiretroviral procurement prices.
Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
[TBL] [Abstract][Full Text] [Related]
3. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
[TBL] [Abstract][Full Text] [Related]
4. Do national drug policies influence antiretroviral drug prices? Evidence from the Southern African Development community.
Liu Y; Galárraga O
Health Policy Plan; 2017 Mar; 32(2):170-177. PubMed ID: 28207060
[TBL] [Abstract][Full Text] [Related]
5. Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
Adesina A; Wirtz VJ; Dratler S
Health Policy Plan; 2013 Jan; 28(1):1-10. PubMed ID: 22375026
[TBL] [Abstract][Full Text] [Related]
6. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
7. Negotiating antiretroviral drug prices: the experience of the Andean countries.
Seoane-Vazquez E; Rodriguez-Monguio R
Health Policy Plan; 2007 Mar; 22(2):63-72. PubMed ID: 17299024
[TBL] [Abstract][Full Text] [Related]
8. Prices & availability of common medicines at six sites in India using a standard methodology.
Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
[TBL] [Abstract][Full Text] [Related]
9. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
10. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
[TBL] [Abstract][Full Text] [Related]
11. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.
Waning B; Diedrichsen E; Jambert E; Bärnighausen T; Li Y; Pouw M; Moon S
BMC Pediatr; 2010 Oct; 10():74. PubMed ID: 20950492
[TBL] [Abstract][Full Text] [Related]
12. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.
Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP
J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142
[TBL] [Abstract][Full Text] [Related]
13. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
Waning B; Kaplan W; King AC; Lawrence DA; Leufkens HG; Fox MP
Bull World Health Organ; 2009 Jul; 87(7):520-8. PubMed ID: 19649366
[TBL] [Abstract][Full Text] [Related]
14. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
[TBL] [Abstract][Full Text] [Related]
15. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
16. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
Waning B; Diedrichsen E; Moon S
J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
[TBL] [Abstract][Full Text] [Related]
17. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
[TBL] [Abstract][Full Text] [Related]
18. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.
Beall RF; Kuhn R; Attaran A
Health Aff (Millwood); 2015 Mar; 34(3):493-501. PubMed ID: 25732501
[TBL] [Abstract][Full Text] [Related]
19. The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund.
Vasan A; Hoos D; Mukherjee JS; Farmer PE; Rosenfield AG; Perriëns JH
Bull World Health Organ; 2006 May; 84(5):393-8. PubMed ID: 16710550
[TBL] [Abstract][Full Text] [Related]
20. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
Beall RF; Attaran A
Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
